NICE recommends semaglutide for secondary cardiovascular prevention in overweight patients, supported by SELECT trial data showing a 20% risk reduction in major events.
Written By: Karthik Teja Macharla, PharmD
Reviewed By: Pharmacally Editorial Team
The National Institute for Health and Care Excellence (NICE) has recommended the use of semaglutide as a preventive treatment for adults at high risk of recurrent cardiovascular events, marking a significant expansion of the drug’s clinical role beyond weight management.
The weekly injectable therapy, widely recognized under the brand Wegovy, will be offered to patients who have previously experienced a heart attack, stroke, or peripheral arterial disease, and who have a body mass index (BMI) of at least 27 kg/m². The treatment is intended to complement standard care, including statins and lifestyle interventions such as diet and physical activity.
Clinical Evidence Supports Cardiovascular Benefit
The recommendation is supported by findings from the SELECT trial (NCT03574597), which enrolled 17,604 patients with established cardiovascular disease. Patients receiving semaglutide alongside standard therapies experienced a 20% reduction in major adverse cardiovascular events, including heart attack, stroke, and cardiovascular death, compared to placebo.
The benefit emerged early in the trial, before significant weight loss was observed. This suggests that semaglutide exerts direct effects on cardiovascular pathways rather than acting solely through weight reduction.
Expanded Eligibility Beyond Weight Management
NICE’s recommendation applies to a broader patient population than its existing guidance on weight management, which requires higher BMI thresholds. By lowering the eligibility criterion to BMI ≥27 kg/m², the guidance extends access to individuals classified as overweight rather than obese.
Approximately 1.2 million people in England could be eligible for this treatment as it becomes available for cardiovascular risk reduction.
Positioning as Add-On Therapy
The therapy is not intended as a replacement for existing cardiovascular medications. Instead, it will be prescribed as an add-on treatment. Patients will not be automatically prescribed semaglutide, and treatment will be initiated only after clinical assessment by a GP or specialist. Eligible patients must also commit to lifestyle modifications, including a reduced-calorie diet and increased physical activity. Patients will self-administer the injection weekly at home once prescribed.
NICE and Clinical Community Perspective
According to Helen Knight, Director of Medicines Evaluation at NICE the clinical evidence demonstrates a meaningful reduction in recurrent cardiovascular events when semaglutide is added to standard therapy. She emphasized that the recommendation balances clinical benefit with cost-effectiveness for the NHS.
Dr Sunil Gupta, GP clinical advisor at NICE highlighted the real-world impact, noting that patients who have already experienced a cardiovascular event often remain at high risk despite adherence to current therapies. He described the injection as an additional tool that can provide further protection in appropriate patients.
Broader Implications
The decision reflects a growing body of evidence supporting the cardiovascular benefits of GLP-1 receptor agonists beyond weight loss. It also aligns with increasing emphasis on secondary prevention in patients with established cardiovascular disease.
Heart and circulatory diseases remain a leading cause of mortality in England, with approximately 100,000 heart attacks and 100,000 strokes occurring annually. Patients with prior events face a significantly elevated risk of recurrence, underscoring the need for additional preventive strategies.
With this recommendation, semaglutide is positioned as a dual-purpose therapy addressing both metabolic and cardiovascular risk, signaling a shift toward more integrated chronic disease management.
References
Injection for more than a million people to help prevent heart attacks and strokes recommended, 01 April 2026, Injection for more than a million people to help prevent heart attacks and strokes recommended | NICE
Michael Lincoff, Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes, N Engl J Med 2023;389:2221-2232, https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity (SELECT), ClinicalTrials.gov ID NCT03574597, https://clinicaltrials.gov/study/NCT03574597
About the Writer
Karthik Teja Macharla, PharmD is a Pharm.D. graduate with a strong interest in clinical research, pharmacovigilance, and medical writing. In his words, he is passionate about converting complex medical information into clear, evidence-based scientific communication, committed to contributing to patient safety and advancing healthcare through accurate and impactful medical content.